H.C. Wainwright analyst Patrick Trucchio maintains $Sangamo Therapeutics (SGMO.US)$ with a buy rating, and maintains the target price at $10.
According to TipRanks data, the analyst has a success rate of 31.5% and a total average return of -0.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Sangamo Therapeutics (SGMO.US)$'s main analysts recently are as follows:
Following the announcement that Pfizer will not proceed with a Biologics License Application for giroctocogene fitelparvovec, a gene therapy candidate for moderately severe to severe hemophilia A, Sangamo was notably taken aback. Despite the surprising turn of events, there remains significant potential for Sangamo in the treatment of Fabry, even under conservative estimates for the project's success.
The analyst notes that the return of Sangamo's hemophilia A program by Pfizer, just prior to the anticipated biologics license application filing, was unexpected. This action means Sangamo misses out on potential regulatory and first-sales milestones amounting to $220M, which increases the funding pressures on Sangamo. The company's current cash reserves are expected to support its operations until the first quarter of 2025, and efforts are underway to partner its Fabry gene therapy program to extend its financial runway.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
H.C. Wainwright分析师Patrick Trucchio维持$Sangamo Therapeutics (SGMO.US)$买入评级，维持目标价10美元。
根据TipRanks数据显示，该分析师近一年总胜率为31.5%，总平均回报率为-0.5%。
此外，综合报道，$Sangamo Therapeutics (SGMO.US)$近期主要分析师观点如下：
辉瑞宣布不会继续处理giroctogene fitelparvovec的生物制剂许可申请（一种治疗中重度至重度甲型血友病的基因疗法），此后，桑加莫大吃一惊。尽管事态发生了令人惊讶的转折，但即使对该项目成功的保守估计，桑加莫在治疗法布瑞方面仍有巨大的潜力。
分析师指出，在预期的生物制剂许可证申请提交之前，辉瑞恢复了桑加莫的A型血友病项目，这出乎意料。这一行动意味着Sangamo错过了总额为2.2亿美元的潜在监管和首次销售里程碑，这增加了Sangamo的资金压力。该公司目前的现金储备预计将在2025年第一季度之前支持其运营，并且正在努力与其Fabry基因疗法计划合作，以延长其财务状况。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
